
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss fiercepharma.com/pharma/fdas…
✓Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.

FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss fiercepharma.com/pharma/fdas…

GSK scores FDA approval for Nelkarmi, its 2nd lung cancer drug from Nuvalent deal fiercepharma.com/pharma/gsk-…

Congratulations to 2026's Fiercest Women in Life Sciences. These leaders have helped develop first-in-class treatments, founded and financed biotechs, and guided experimental therapies through clinical development. fiercepharma.com/special-rep…

FDA rejects Summit Therapeutics’ ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class fiercepharma.com/pharma/fda-…

When most buyers of FDA priority review vouchers remain anonymous, BioNTech says it’ll pay $205M for a PRV to speed up its ‘late-stage oncology pipeline’ fiercepharma.com/pharma/bion…

Summit Therapeutics quietly parted ways with its chief commercial officer and other commercial leaders responsible for building the launch plan of ivonescimab. fiercepharma.com/pharma/summ…

Revolution Medicines' Rasonque generated nearly $200M sales in its first five weeks on the market, living up to its much-hyped potential fiercepharma.com/pharma/revm…

AstraZeneca said to offer $10B to acquire Rhythm Pharmaceuticals; analysts whisper of a bidding war fiercepharma.com/pharma/astr…

Novo catches Wegovy pill tailwind in Q3 as CEO eyes new launch horizons in 2027 fiercepharma.com/pharma/novo…

Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up fiercepharma.com/pharma/madr…

Madrigal’s Rezdiffra storms past blockbuster milestone as CEO hails ‘accelerating’ MASH market fiercepharma.com/pharma/madr…

Bayer’s pharma business may finally be entering a growth cycle, but CEO Bill Anderson still can’t quite escape questions around a potential business split. fiercepharma.com/pharma/baye…

Karyopharm enters bankruptcy, lines up Ayrmid as lead bidder in planned merger fiercepharma.com/pharma/kary…

Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…

In sac-TMT’s first global phase 3 win, Merck sees ‘pretty consistent’ data with China. #ESMO26 fiercepharma.com/pharma/sac-…

‘5 out of 5’ phase 3 wins for BMS’ bispecific ADC iza-bren. So why hasn’t CMO Cristian Massacesi matched one of those China successes with a global phase 3 yet? #ESMO26 fiercepharma.com/pharma/bris…